

Pneumatic Compression Devices

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Pneumatic compression devices, or PCDs, are a type of durable medical equipment that are used to improve venous blood return and lymphatic fluid movement. The device involves an inflatable garment and a pump; the pump inflates the garment with air to compress a specific body part with the goal of forcing blood or lymph fluid away from the compressed area. This can be therapeutic in patients who may require additional care over static compression therapy (in which bandages or hosiery are used to apply a constant pressure gradient along an affected limb). There are many variations including unicompartmental devices with or without manual control, multicompartmental devices with or without manual control, high pressure rapid inflation pumps, two-stage multichamber programmable PCDs, and combination cold/compression pumps. Certain compression devices are not appropriate for all types of venous and lymphatic return impairments (e.g., diabetic neuropathy, cancer lesions, infections, etc.), and consultation with your healthcare provider can help determine the best initial therapy.

Definitions

"Pneumatic compression" refers to the use of air to inflate and deflate a cuff to mimic a rhythmic squeezing motion.

"Unicompartmental devices," or non-segmented devices, are a type of appliance that has only one inflatable chamber. These are typically used with a compressor that has a single outflow tube and allows for an equal amount of pressure to be applied across the entire device.

"Multicompartmental devices," or segmented devices, are a type of appliance where there are multiple inflatable chambers. These can be used with a compressor that has a single outflow tube, similar to unicompartmental devices, but certain designs of the chambers can allow for a gradient of pressure to be applied, meaning that one compartment can have less pressure than the adjacent compartment. The different inflatable chambers are preset and cannot be manually changed in non-programmable devices.

"Calibrated gradient pressure" (e.g., programmable) is a feature of certain devices where the compressor has multiple outflow tubes that allow for the individual to manually control the pressure in three or more inflatable chambers. This is an advanced feature that allows adjustment of pressure for unicompartmental programmable or multicompartmental programmable devices.

"Advanced multi-compartmental programmable pneumatic compression devices," also known as "advanced pneumatic compression devices (APCDs)," are multi-chamber devices that inflate at different times. They work by first applying pressure to the proximal tissues, followed by compression of the distal extremity, similar to manual lymph drainage. The initial compression is usually proximal to the affected extremity, (e.g., the "preparatory stage"), followed by a second programmed compression of the affected extremity, (e.g., the "drainage" stage).

"High pressure rapid inflation" devices are similar to traditional PCDs described above, except they apply significantly higher pressure and cycle more rapidly. These have been proposed for the treatment of arterial insufficiency, i.e., peripheral arterial disease.

"Immobile" or "bedridden" describes a clinical scenario when a member has limited mobility to leave the bed and/or limited ability to turn and position for self-care within the bed. This can be transient, such as recovery from a major orthopedic surgery or trauma, or it can be permanent, such as loss of motor function after spinal cord injury. A state of immobility can increase the risk of deep venous thrombosis and subsequent pulmonary emboli.

"Lymphedema" is a condition where the lymph channels are obstructed or damaged (from skin infections, surgery, radiation, etc.) causing inadequate lymph fluid return and resulting in swelling of the tissues in the affected region. The causes can be various in nature such as genetic, post-surgery, trauma, infection, or skin disorders.

"Deep vein thrombosis (DVT)" is a condition where a blood clot forms in one of the deep veins, which can be associated with acquired syndrome, genetic factors, or prolonged immobilization. Using a PCD on a limb with known or suspected DVT could result in a pulmonary embolism as the movement of the PCD could dislodge the clot that can travel and lodge in the lung, which can be fatal.

“Chronic venous insufficiency” is a condition where the vein valves in the legs fail to properly close, resulting in progressive pooling of blood in the affected extremity. When the blood is not well circulated, the local tissues can be damaged resulting in edema and the formation of stasis ulcers.

A. Clinical Indications

1. Medical Necessity Criteria for Initial Clinical Review

- a. General Medical Necessity Criteria
- b. Initial Indication-Specific Criteria

Continued Care

2. Medical Necessity Criteria for Subsequent Clinical Review

- a. Subsequent Medical Necessity Criteria

3. Experimental or Investigational / Not Medically Necessary

B. Applicable Billing Codes

C. References

Medical Necessity Criteria for Initial Clinical Review

General Medical Necessity Criteria

The Plan considers unicompartamental or multicompartamental pneumatic compressors with or without calibrated gradient pressure medically necessary when ALL of the following criteria are met:

1. Expected duration of injury, disease, and/or immobility must be provided; *and*
2. The member's medical history including any contraindication and/or trial and failure of conservative therapy has been documented in the medical record; *and*
3. The PCD will not be used on a limb with a suspected or known DVT.

Initial Indication-Specific Criteria

Non-Programmable Pneumatic Compression Devices

The Plan considers unicompartamental or multicompartamental pneumatic compressors without calibrated gradient pressure (e.g., non-programmable) medically necessary for initial requests for limbs when the General Medical Necessity Criteria are met and ONE of the following is present:

1. Deep venous thrombosis (DVT) prevention for members who meet all of the following:
 - a. Immobile or bedridden, as defined above; *and*
 - b. Member is unable to use other compression interventions such as compression stockings due to specific medical comorbidities or contraindications; *and*
 - c. Member has no absolute contraindications, including, but not limited to:
 - i. Arterial occlusive disease with an ankle-brachial pressure index <0.5; *or*
 - ii. NYHA Class III or IV heart failure; *or*
 - iii. Suspected or known DVT; *or*
 - iv. Acute cellulitis, infection, or necrotic tissue; *or*
2. Chronic venous insufficiency with venous stasis ulcers in members who meet BOTH of the following:

- a. Failure to show decrease in size and/or symptoms after at least 6 months of conservative therapy, which includes ALL of the following (or contraindications to the following):
 - i. Compression garment or bandage system; *and*
 - ii. Appropriate dressing for wound; *and*
 - iii. Exercise; *and*
 - iv. Elevation of the limb; *and*
 - v. Underlying cause is treated, if possible; *and*
 - b. Member has no absolute contraindications, including, but not limited to:
 - i. Arterial occlusive disease with an ankle-brachial pressure index <0.5; *or*
 - ii. NYHA Class III or IV heart failure; *or*
 - iii. Suspected or confirmed recent acute DVT (unless member is in therapeutic range on anticoagulation); *or*
 - iv. Acute cellulitis, infection, or necrotic tissue; *or*
3. Symptomatic lymphedema that meets ALL the following:
- a. Documentation of ONE of the following:
 - i. Lymphedema with skin involvement (e.g., dermal fibrosis, ulcers, scarring); *or*
 - ii. Medical records confirming persistent lymphedema; *and*
 - b. Member meets ONE of the following:
 - i. A 4-week trial of conservative therapy fails to resolve the condition. If there is initial improvement of lymphedema, therapy should continue until there are 4 weeks of non-resolving lymphedema. Conservative therapy should include ALL the following treatments:
 - 1. Compression garment or bandage system; *and*
 - 2. Regular exercise if possible; *and*
 - 3. Elevation of the limb; *or*
 - ii. The member is unable to use other compression interventions such as compression bandages or garments due to specific medical comorbidities or contraindications.

Programmable Pneumatic Compression Devices

The Plan considers unicompartamental or multicompartamental pneumatic compressors with calibrated gradient pressure (e.g., programmable) medically necessary for initial requests for limbs or two-phase or two-stage segmental home models with calibrated gradient pressure (e.g., Flexitouch System application for limbs only) when the General Medical Necessity Criteria are met and ONE of the following is present:

- 1. Lymphedema that extends onto the chest, trunk, or abdomen and meets ONE of the following:
 - a. Prior 4 week trial of therapy with a non-programmable PCD without calibrated gradient pressure that failed to resolve lymphedema. This requires previous conservative therapy to be tried first, as outlined above such as a 4-week trial of compression garment/bandage system. Therapy trial should include all of the following:
 - i. Usage of a non-programmable PCD without calibrated gradient pressure for at least 4 weeks; *and*

- ii. Regular exercise if possible; *and*
 - iii. Elevation; *and*
 - iv. Manual lymphatic drainage where appropriate; *and*
 - v. Diet changes if necessary; *and*
 - vi. Medications if appropriate; *and*
 - vii. Anemia or hypoproteinemia correction; *or*
 - b. Documentation of unique characteristics (e.g., contracture, skin sensitivity, and/or significant scarring) that prevents treatment using a PCD without calibrated gradient pressure; *or*
2. Chronic venous stasis ulcers that meet ONE of the following:
- a. Member has not responded to 4 weeks of appropriate treatment with a unicompartmental or multicompartmental pneumatic compressor without a calibrated gradient pressure and continues to meet criteria above; *or*
 - b. Documentation of unique characteristics prevents treatment using a PCD without calibrated gradient pressure (e.g. ulcer pain limits use).

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent Medical Necessity Criteria

Continued use of the pneumatic compression device (e.g., unicompartmental, multicompartmental, non-calibrated/non-programmable, calibrated gradient pressure/programmable, two-phase devices) is considered medically necessary for limbs (e.g., arms and/or legs) when ALL of the following criteria are met:

1. There is documented adherence with the use of the device as prescribed by the treating healthcare professional; *and*
2. Medical records document clinical improvement in the condition being treated; *and*
3. There is reasonable expectation that continued use of the device will continue to improve the member's condition or prevent further decompensation.

The medical necessity criteria for Continued Care applies to pneumatic compression devices that the member is currently using for the reauthorization for limbs only (e.g., arms and/or legs). This includes "two-phase" devices with initial external compression therapy applied (pneumomassage) and then form-fitting low-stretch elastic stockings or sleeves are used to maintain edema reduction for limbs. Also, this includes "two-stage" devices with initial programmed compression of the proximal areas, the "preparatory stage," followed by a second programmed compression of the distal areas of the affected limb(s), the "drainage" stage.

Experimental or Investigational / Not Medically Necessary

Pneumatic compression devices are not considered medically necessary by the Plan for any indication not listed in the medical necessity criteria, including, but not limited to:

1. Application of pneumatic compression devices (non-programmable and programmable) directly to the abdomen, chest, or trunk for edema or lymphedema

Pneumatic compression devices are considered experimental, investigational, or unproven for the following indications, due to insufficient evidence in peer-reviewed medical literature to establish clinical effectiveness. These indications include, but are not limited to:

1. Arterial insufficiency
2. Critical limb ischemia
3. Head or neck lymphedema
4. Distal radial fracture management
5. Decompensated heart failure (New York Heart Association Class IV)
6. Edema after lower extremity bypass surgery (e.g., femoropopliteal bypass surgery)
7. Fractures and soft-tissue injuries
8. Restless leg syndrome
9. Sensory impairment in upper limb extremities in stroke patients
10. Upper extremity vascular ulcers

Not all pneumatic compression devices have been shown to have significantly improved outcomes as compared to standard devices, thus not all devices are considered medically necessary by the Plan.

Devices that are considered experimental, investigational, or unproven include, but are not limited to:

1. Intermittent pneumatic compression devices with sustained gradient pressure (e.g., ACTitouch Adaptive Compression Therapy System)
2. Intermittent pneumatic compression devices with combination cold or heat therapy (e.g., Cotherra VPULSE, NanoTherm, VascuTherm, Kinex ThermoComp)
3. Pneumatic compression pumps with high pressure rapid inflation (e.g., FlowMedic FM220, AirCast VenaFlow Elite System)
4. Intermittent pneumatic compression devices for single patient use (e.g., VenaPro)
5. Other advanced multi-compartmental pneumatic compression devices, such as two-phase or two-stage lymph preparation and drainage devices for use directly on the head, neck, chest, abdomen, or trunk (e.g., Flexitouch System, Flexitouch Plus System)

Evidence

Fractures and soft-tissue injuries

Khanna et al. performed a database search to investigate the use of pneumatic compression devices (PCDs) in fractures and soft-tissue injuries. Their review included sixteen studies between 1989 and 2007, nine of which were human studies, and seven of which were animal studies. They concluded that PCDs are safe and effective for fracture and soft-tissue injuries, but that the limited numbers of patients in the

human studies made the evidence unreliable. Larger randomized controlled trials are needed to confirm these findings and establish the potential role of PCDs in fracture and soft-tissue injury management.

Edema after femoropopliteal bypass surgery

Te Slaa et al. (2011) performed a prospective randomized trial to observe the effect of using pneumatic compression devices (PCDs) in patients who underwent post-op femoropopliteal bypass surgery. They compared groups using either compression stockings or a PCD and found that compression stockings were more effective at preventing and treating edema.

Decompensated heart failure (NYHA Class IV)

According to a 2020 international consensus statement published in *Phlebology*, application of compression is not recommended in severe cases of cardiac insufficiency (NYHA class IV) because compression of both legs may lead to asymptomatic increase in cardiac preload and temporary strain on the heart.

Distal radial fracture management

Handoll and Elliott (2015) performed an updated Cochrane Database Review of management of distal radial fractures, including 26 trials of 1269 patients. Regarding PCDs, only 31 patients received this treatment, indicating very low-quality evidence. The authors concluded that the evidence is insufficient to support any role of PCD in rehabilitation of distal radial fractures.

Critical limb ischemia

Moran et al. (2015) conducted a systematic literature review to evaluate the efficacy of PCDs in critical limb ischemia. Early hypotheses suggested that PCDs could assist in wound healing and reduce limb amputation risk. The authors identified eight studies that addressed PCD use in limb ischemia, all of which had a high risk of bias. They concluded that the existing evidence does not support the efficacy of PCDs for the treatment of limb ischemia. Another systematic review conducted by Abu Dabrh et al. (2015) compared medical therapy to PCD management in the treatment of critical limb ischemia. They found some suggestions that PCDs could reduce amputation risk, but the evidence was similarly low quality and thus inconclusive. The American Heart Association and American College of Cardiology recently reviewed the role of PCDs in critical limb ischemia and concluded that the evidence was insufficient to support their use for pain relief or wound healing.

Restless leg syndrome

Lettieri and Eliasson (2009) conducted a randomized controlled trial (RCT) with 35 patients to evaluate efficacy of utilizing pneumatic compression devices (PCDs) in patients with restless leg syndrome (RLS). The study found statistically significant improvements in symptom severity, quality of life, daytime sleepiness, and fatigue in patients using therapeutic PCDs compared to sham devices. However, the small sample size and short duration of the trial limit the generalizability and robustness of these findings. Further large-scale, long-term RCTs are needed to confirm the clinical effectiveness of PCDs in RLS. Therefore, PCDs are currently considered experimental for the treatment of RLS.

Sensory impairment in upper extremities in stroke patients

Sensory loss of upper extremities can be common in patients who have a stroke, and medical research has tried to identify what interventions may be helpful in regaining sensation. Doyle et al. reviewed 13 studies looking at interventions and found that there were no clear conclusions on the effectiveness of many of the currently used therapies. They found preliminary evidence for the use of PCDs in helping to regain sensation, but there were limited numbers of studies that included PCD as an intervention. Thus, PCDs are currently considered experimental in the treatment of sensory impairment for stroke patients.

Upper extremity vascular ulcers

While PCDs have demonstrated utility in the management of lower extremity ulcers, their role in the treatment of upper extremity ulcers remains unclear. A 2005 pilot study of 26 patients reported an association between PCD use and ulcer healing. However, the study lacked a comparison group, limiting the ability to determine whether PCDs provide a therapeutic benefit for upper extremity ulcers. The limited evidence base may be due, in part, to the lower prevalence of upper extremity ulcers compared to lower extremity ulcers. Therefore, PCDs are currently considered experimental for the treatment of upper extremity ulcers.

Arterial Insufficiency

A prospective randomized clinical trial was conducted by te Slaa et al (2011) comparing compression stockings (CS) with intermittent pneumatic compression (IPC) for 57 patients undergoing femoral-popliteal bypass surgery for arterial insufficiency. They concluded that, "for the prevention and treatment of that edema the use of a class I [compression stocking] proved superior to treatment with IPC. The use of CS remains the recommended practice following femoropopliteal bypass surgery." Further studies are needed to determine any potential benefit of PCDs in this patient population.

Advanced multi-compartmental programmable pneumatic compression devices (e.g., Flexitouch or Flexitouch Plus System) for the chest, abdomen, or trunk

The available evidence evaluating advanced pneumatic compression devices (APCDs), such as the Flexitouch or Flexitouch Plus System, for lymphedema of the chest, abdomen, or trunk is limited and inconclusive. In a 2011 randomized controlled trial (RCT) by Ridner et al., 42 participants were randomized to receive either advanced pneumatic truncal, chest, and arm treatment or arm treatment only for self-care of arm lymphedema. The study found "a statistically significant reduction in both the number of symptoms and overall symptom burden within each group; however, there were no statistically significant differences in these outcomes between the groups. There was no statistically significant overall change or differential pattern of change between the groups in function." All other measured parameters showed no statistical difference. The authors concluded that "both configurations are effective, but that there may be no added benefit to advanced pneumatic treatment of the truncal lymphatics prior to arm massage when the trunk is not also affected." Overall, the evidence base lacks large-scale, high-quality RCTs comparing APCDs to standard care or conservative measures for truncal lymphedema and is thus insufficient to establish definitive conclusions about the clinical effectiveness or long-term benefits of APCDs for this clinical indication.

Head or neck lymphedema / Advanced multi-compartmental programmable pneumatic compression devices (e.g., Flexitouch or Flexitouch Plus System) for the head or neck

A small but emerging body of evidence has evaluated advanced pneumatic compression devices (APCDs), such as the Flexitouch or Flexitouch Plus System, for treatment of head and neck lymphedema (HNL). This includes one randomized controlled trial (RCT) and four small quasi-experimental studies (Gregor et al., 2024; Gutierrez et al., 2019; Gutierrez et al., 2020; Mayrovitz et al., 2017; Ridner et al., 2020). The four quasi-experimental studies were nonrandomized pre/post designs, which are at high risk of bias, and all were feasibility or early-stage studies designed to evaluate usability rather than long-term clinical outcomes. Across all five studies, follow-up was short term (ranging from immediate use to 8 weeks), with no data on long-term safety, durability, or sustained clinical benefit. While some studies reported short-term improvement in swelling, pain, or function, the methodological limitations make it unclear whether these changes are clinically meaningful or attributable to the device.

The only RCT (Ridner et al., 2020) used a randomized wait-list controlled design with an 8-week comparison period, after which all participants could opt to receive the device. While this design included a short-term comparator arm, the limited duration limits assessment of long-term clinical effectiveness. The study was also underpowered due to a small sample size (49 participants). Additionally, the comparator was wait-list lymphedema self-management alone, not the established standard of care for lymphedema, which is complete decongestive therapy (CDT). Thus, conclusions cannot be drawn from this study about whether the Flexitouch is equivalent or superior to CDT.

Additionally, a Hayes Evolving Evidence Review (updated 2024) assessed four of the five above studies on the use of the Flexitouch Plus System for treatment of HNL. Hayes rated the evidence quality as very poor to poor, citing small sample sizes, short follow-up, use of non-validated assessment tools, and limited statistical rigor. Hayes concluded that there is minimal support from full-text clinical studies and no support from systematic reviews or clinical practice guidelines for the use of the Flexitouch Plus System in treating HNL, and that whether the device provides a durable or clinically significant benefit over other HNL treatment options remains uncertain due to limited comparative clinical evidence. Finally, the clinical trial cited in the 2016 FDA 510(k) K153311 approval for the Flexitouch included no comparison group for head/neck versus limb use, no control group receiving standard care or conservative measures, and no head-to-head comparison with other devices to determine whether the Flexitouch provides greater or equivalent benefit for HNL. Overall, the evidence base lacks large-scale, high-quality RCTs and is thus insufficient to establish definitive conclusions about the clinical effectiveness or long-term benefits of APCDs for HNL.

Applicable Billing Codes

Table 1	
Pneumatic Compression Devices	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
A4600	Sleeve for intermittent limb compression device, replacement only, each
E0650	Pneumatic compressor, nonsegmental home model
E0651	Pneumatic compressor, segmental home model without calibrated gradient pressure
E0652	Pneumatic compressor, segmental home model with calibrated gradient pressure
E0655	Non-segmental pneumatic appliance for use with pneumatic compressor, half arm
E0660	Non-segmental pneumatic appliance for use with pneumatic compressor, full leg
E0666	Non-segmental pneumatic appliance for use with pneumatic compressor, half leg
E0667	Segmental pneumatic appliance for use with pneumatic compressor, full leg
E0668	Segmental pneumatic appliance for use with pneumatic compressor, full arm
E0669	Segmental pneumatic appliance for use with pneumatic compressor, half leg
E0671	Segmental gradient pressure pneumatic appliance, full leg
E0672	Segmental gradient pressure pneumatic appliance, full arm
E0673	Segmental gradient pressure pneumatic appliance, half leg
E0676	Intermittent limb compression device (includes all accessories) not otherwise specified

Table 2	
ICD-10 codes considered medically necessary with Table 1 codes if criteria are met:	
<i>Code</i>	<i>Description</i>
I83.001 - I83.029	Varicose veins of lower extremities with ulcer
I83.201 - I83.229	Varicose veins of unspecified lower extremity with both ulcer and inflammation
I87.2	Venous insufficiency (chronic) (peripheral)
I87.331 - I87.339	Chronic venous hypertension (idiopathic) with ulcer and inflammation
I89.0 - I89.9	Other noninfective disorders of lymphatic vessels and lymph nodes
I97.2	Postmastectomy lymphedema syndrome
L97.101 - L97.929	Non-pressure chronic ulcer of lower limb, not elsewhere classified
Q82.0	Hereditary lymphedema
Z74.01	Bed confinement status

Table 3	
ICD-10 codes considered experimental or investigational with Table 1 codes:	
<i>Code</i>	<i>Description</i>
G25.81	Restless legs syndrome
I50.22	Chronic systolic (congestive) heart failure
I50.32	Chronic diastolic (congestive) heart failure
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure
I50.812	Chronic right heart failure
I50.84	End stage heart failure
I82.401 - I82.4Z9	Acute embolism and thrombosis of deep veins of lower extremity

Table 3	
ICD-10 codes considered experimental or investigational with Table 1 codes:	
<i>Code</i>	<i>Description</i>
I99.8	Other disorder of circulatory system
L03.011 - L03.91	Cellulitis and acute lymphangitis
M62.20 - M62.28	Nontraumatic ischemic infarction of muscle
S00.00XA - S09.90XS	Injuries to the head
S10.0XXA - S19.9XXS	Injuries to the neck
S20.00XA - S29.9XXS	Injuries to the thorax
S30.0XXA - S39.94XS	Injuries to the abdomen, lower back, lumbar spine, pelvis and external genitals
S40.011A - S49.92XS	Injuries to the shoulder and upper arm
S50.00XA - S59.919S	Injuries to the elbow and forearm
S60.011A - S69.92XS	Injuries to the wrist, hand and fingers
S70.00XA - S79.929S	Injuries to the hip and thigh
S80.00XA - S89.92XS	Injuries to the knee and lower leg
S90.00XA - S99.929S	Injuries to the ankle and foot

Table 4	
CPT/HCPCS codes <u>not considered medically necessary</u> for indications in this guideline:	
<i>Code</i>	<i>Description</i>
E0218	Water circulating cold pad with pump, any type
E0236	Pump for water circulating pad
E0652	Pneumatic compressor, segmental home model with calibrated gradient pressure • <u>Due to multiple products represented by this CPT/HCPCS code, specific exclusions are indicated:</u> • When this code is billed for Flexitouch for any other indication than limbs, it is considered not medically necessary.

Table 5	
CPT/HCPCS codes considered experimental or investigational for indications in this guideline:	
<i>Code</i>	<i>Description</i>
E0651	Pneumatic compressor, segmental home model without calibrated gradient pressure • <u>Due to multiple products represented by this CPT/HCPCS, specific exclusions are indicated:</u> • When this code is billed for cold/heat therapy or for the ActiTouch Adaptive Compression Therapy System, it is considered experimental/investigational
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest
E0670	Segmental pneumatic appliance for use with pneumatic compressor; integrated, 2 full legs and trunk
E0675	Pneumatic compression device, high pressure, rapid inflation/deflation cycle for arterial insufficiency (unilateral or bilateral system)
E0676	Intermittent limb compression device (includes all accessories) not otherwise specified

	• <u>Due to multiple products represented by this CPT/HCPCS code, specific exclusions are indicated:</u> • When this code is billed for the Cotherra VPULSE or VenaPro, it is considered experimental/investigational
--	--

References

1. Anderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., Smythe, M. A., Tikkinen, K. A. O., Yates, A. J., Baldeh, T., Balduzzi, S., Brožek, J. L., Ikbaltzeta, I. E., Johal, H., Neumann, I., Wiercioch, W., ... Dahm, P. (2019). American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood advances*, 3(23), 3898–3944. <https://doi.org/10.1182/bloodadvances.2019000975>
2. Andriessen, A., Apelqvist, J., Mosti, G., Partsch, H., Gonska, C., & Abel, M. (2017). Compression therapy for venous leg ulcers: Risk factors for adverse events and complications, contraindications - a review of present guidelines. *Journal of the European Academy of Dermatology and Venereology*, 31(9), 1562–1568. <https://doi.org/10.1111/jdv.14390>
3. Armer, J. M., Ostby, P. L., Ginex, P. K., Beck, M., Deng, J., Fu, M. R., Lasinski, B. B., Lockwood, S., Poage, E., White, J., Maloney, C., Moriarty, K. A., Vrabel, M., & Morgan, R. L. (2020). ONS Guidelines™ for cancer treatment-related lymphedema. *Oncology Nursing Forum*, 47(5), 518–538. <https://doi.org/10.1188/20.ONF.518-538>
4. Armstrong, D.G., & Meyr, A. (2025). Compression therapy for treatment of chronic venous insufficiency. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/compression-therapy-for-the-treatment-of-chronic-venous-nsufficiency>
5. Blumberg, S. N., Berland, T., Rockman, C., Mussa, F., Brooks, A., Cayne, N., & Maldonado, T. (2016). Pneumatic compression improves quality of life in patients with lower-extremity lymphedema. *Annals of Vascular Surgery*, 30, 40–44. <https://doi.org/10.1016/j.avsg.2015.07.004>
6. Centers for Medicare & Medicaid Services. (2002, January 14). National Coverage Determination (NCD) for Pneumatic Compression Devices (280.6). Retrieved from <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=225>
7. Cohen, A., Gaebler, J. A., Izhakoff, J., Gullett, L., Niecko, T., & O'Donnell, T. (2018). US budget impact of increased payer adoption of the Flexitouch advanced pneumatic compression device in lymphedema patients with advanced chronic venous insufficiency and multiple infections. *Journal of Medical Economics*, 21(10), 993–1000. <https://doi.org/10.1080/13696998.2018.1491008>
8. De-La-Cruz-Fernández, L., Galiano-Castillo, N., Galván-Banqueri, P., Castro-Martín, E., Lozano-Lozano, M., Postigo-Martin, P., & Lopez-Garzon, M. (2025b). Lymphedema management in patients with head and neck cancer: A systematic review of randomized controlled trials on

- physical therapy interventions. *Supportive Care in Cancer*, 33(5).
<https://doi.org/10.1007/s00520-025-09438-1>
9. Desai, S. S., Shao, M., & Vascular Outcomes Collaborative (2020). Superior clinical, quality of life, functional, and health economic outcomes with pneumatic compression therapy for lymphedema. *Annals of Vascular Surgery*, 63, 298–306.
<https://doi.org/10.1016/j.avsg.2019.08.091>
 10. Donahue, P. M. C., MacKenzie, A., Filipovic, A., & Koelmeyer, L. (2023). Advances in the prevention and treatment of breast cancer-related lymphedema. *Breast Cancer Research and Treatment*, 200(1), 1–14. <https://doi.org/10.1007/s10549-023-06947-7>
 11. Douketis, J.D., & Mithoowani, S. (2025). Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients. *UpToDate*. Retrieved from
<https://www.uptodate.com/contents/prevention-of-venous-thromboembolic-disease-in-adult-nonorthopedic-surgical-patients>
 12. Executive Committee of the International Society of Lymphology (2023). The diagnosis and treatment of peripheral lymphedema: 2023 Consensus Document of The International Society of Lymphology. *Lymphology*, 56(4), 133–151.
 13. Food and Drug Administration. (2016, August). *Flexitouch System. 510(k) Number K153311*. Retrieved on July 7, 2021 from https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153311.pdf
 14. Fukaya, E., O'Banion, L.A., Kiguchi, M., & Judelson, D.R. (2025). Evaluation and management of chronic venous insufficiency including venous leg ulcer. *UpToDate*. Retrieved from
<https://www.uptodate.com/contents/evaluation-and-management-of-chronic-venous-insufficiency-including-venous-leg-ulcer>
 15. Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., Evans, J. N., Getchius, T. S. D., Gutiérrez, J. A., Hawkins, B. M., Hess, C. N., Ho, K. J., Jones, W. S., Kim, E. S. H., Kinlay, S., Kirksey, L., ... Peer Review Committee Members (2024). 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VES guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 149(24), e1313–e1410. <https://doi.org/10.1161/CIR.0000000000001251>
 16. Gregor, J. W., Chang, B., Keole, N., McGary, A., & Patel, S. (2024). Initial proof-of-concept study on immediate effects of external advanced pneumatic compression on pharyngeal and laryngeal internal lymphedema using a fluoroscopic measurement tool. *Head & Neck*.
<https://doi.org/10.1002/hed.27983>
 17. Gutierrez, C., Karni, R. J., Naqvi, S., Aldrich, M. B., Zhu, B., Morrow, J. R., Sevic-Muraca, E. M., & Rasmussen, J. C. (2019). Head and neck lymphedema: Treatment response to single and multiple sessions of advanced pneumatic compression therapy. *Otolaryngology*, 160(4), 622–626. <https://doi.org/10.1177/0194599818823180>
 18. Gutiérrez, C., Mayrovitz, H. N., Naqvi, S. H. S., & Karni, R. J. (2020). Longitudinal effects of a novel advanced pneumatic compression device on patient-reported outcomes in the

- management of cancer-related head and neck lymphedema: A preliminary report. *Head & Neck*, 42(8), 1791–1799. <https://doi.org/10.1002/hed.26110>
19. Hayes Inc. Evidence Analysis Research Brief. *Flexitouch Plus System (Tactile Medical) for Lymphedema of the Head and Neck*. Lansdale, PA: Hayes, Inc.; October 2024.
 20. Hayes, Inc. Evidence Analysis Research Brief. *Pneumatic Compression for Prevention of Deep Vein Thrombosis After Shoulder Surgery*. Lansdale, PA: Hayes, Inc.; December 2021.
 21. Hayes, Inc. Evidence Analysis Research Brief. *Pneumatic Compression for Prevention of Deep Vein Thrombosis Following Hip Surgery*. Lansdale, PA: Hayes, Inc.; October 2022.
 22. Hayes, Inc. Evolving Evidence Review. *Home Use of Pneumatic Compression Devices for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty*. Lansdale, PA: Hayes, Inc.; October 2024.
 23. Hayes, Inc. Health Technology Assessment. *Pneumatic Compression For Prevention Of Deep Vein Thrombosis Following Knee Arthroplasty*. Lansdale, PA: Hayes, Inc.; January 2023.
 24. Ishida, K. (2025). Complications of stroke: An overview. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/complications-of-stroke-an-overview>
 25. Karaca-Mandic, P., Hirsch, A. T., Rockson, S. G., & Ridner, S. H. (2017). A comparison of programmable and nonprogrammable compression devices for treatment of lymphoedema using an administrative health outcomes dataset. *The British Journal of Dermatology*, 177(6), 1699–1707. <https://doi.org/10.1111/bjd.15699>
 26. Korschake, W., Riebe, H., Vollmer, M., & Jünger, M. (2022). Optimisation of intermittent pneumatic compression in patients with lymphoedema of the legs. *Optimisation of intermittent pneumatic compression in patients with lymphoedema of the legs. European Journal of Dermatology*, 32(6), 781–792. <https://doi.org/10.1684/ejd.2022.4382>
 27. Lettieri, C. J., & Eliasson, A. H. (2009). Pneumatic compression devices are an effective therapy for restless legs syndrome: A prospective, randomized, double-blinded, sham-controlled trial. *Chest*, 135(1), 74–80. <https://doi.org/10.1378/chest.08-16650>
 28. Li, J. X., Gao, J., Song, J. Y., Li, H. P., Yang, W. J., Tong, D. T., & Zou, Y. (2022). Compression therapy for the patients with breast cancer: A meta-analysis of randomized controlled trials. *Cancer Nursing*, 45(4), E736–E745. <https://doi.org/10.1097/NCC.0000000000001005>
 29. Lurie, F., Malgor, R. D., Carman, T., Dean, S. M., lafrati, M. D., Khilnani, N. M., Labropoulos, N., Maldonado, T. S., Mortimer, P., O'Donnell, T. F., Jr, Raffetto, J. D., Rockson, S. G., & Gasparis, A. P. (2022). The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment. *Phlebology*, 37(4), 252–266. <https://doi.org/10.1177/02683555211053532>
 30. Maldonado, T. S., Rokosh, R. S., Padberg, F., Rotella, V., Miller, H., Nassiri, N., Jacobowitz, G., Berland, T., Sadek, M., & Barfield, M. E. (2021). Assessment of quality of life changes in patients with lower extremity lymphedema using an advanced pneumatic compression device at home. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, 9(3), 745–752. <https://doi.org/10.1016/j.jvsv.2020.10.013>

31. Mayrovitz, H. N., Ryan, S., & Hartman, J. M. (2017). Usability of advanced pneumatic compression to treat cancer-related head and neck lymphedema: A feasibility study. *Head & Neck*, 40(1), 137–143. <https://doi.org/10.1002/hed.24995>
32. MCG Health. (2025). *Intermittent Pneumatic Compression with Extremity Pump*. In *Ambulatory Care* (29th ed.). Retrieved from https://careweb.careguidelines.com/ed29/ac/ac05_017.htm
33. Moran, P. S., Teljeur, C., Harrington, P., & Ryan, M. (2015). A systematic review of intermittent pneumatic compression for critical limb ischaemia. *Vascular Medicine* (London, England), 20(1), 41–50. <https://doi.org/10.1177/1358863X14552096>
34. Mullan, L. J., Blackburn, N. E., Gracey, J., Dunwoody, L., Lorimer, J., & Semple, C. J. (2023). Evaluating the effects of lymphoedema management strategies on functional status and health-related quality of life following treatment for head and neck cancer: A systematic review. *Journal of Cancer Survivorship*. <https://doi.org/10.1007/s11764-023-01453-7>
35. National Guideline Centre (UK). (2018). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. National Institute for Health and Care Excellence (NICE). Retrieved from from: <https://www.ncbi.nlm.nih.gov/books/NBK493720/>
36. Nelson, E. A., Hillman, A., & Thomas, K. (2014). Intermittent pneumatic compression for treating venous leg ulcers. *The Cochrane Database of Systematic Reviews*, 2014(5), CD001899. <https://doi.org/10.1002/14651858.CD001899.pub4>
37. Nickles, M. A., Ennis, W. J., O'Donnell, T. F., Jr, & Altman, I. A. (2023). Compression therapy in peripheral artery disease: A literature review. *Journal of Wound Care*, 32(Sup5), S25–S30. <https://doi.org/10.12968/jowc.2023.32.Sup5.S25>
38. O'Donnell, T. F., Passman, M. A., Marston, W. A., Ennis, W. J., Dalsing, M., Kistner, R. L., Lurie, F., Henke, P. K., Gloviczki, M. L., Eklöf, B. G., Stoughton, J., Raju, S., Shortell, C. K., Raffetto, J. D., Partsch, H., Pounds, L. C., Cummings, M. E., Gillespie, D. L., McLafferty, R. B., . . . Gloviczki, P. (2014). Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. *Journal of Vascular Surgery*, 60(2), 3S-59S. <https://doi.org/10.1016/j.jvs.2014.04.049>
39. Rabe, E., Partsch, H., Morrison, N., Meissner, M. H., Mosti, G., Lattimer, C. R., Carpentier, P. H., Gaillard, S., Jünger, M., Urbanek, T., Hafner, J., Patel, M., Wu, S., Caprini, J., Lurie, F., & Hirsch, T. (2020). Risks and contraindications of medical compression treatment - A critical reappraisal. An international consensus statement. *Phlebology*, 35(7), 447–460. <https://doi.org/10.1177/0268355520909066>
40. Ridner, S. H., Dietrich, M. S., Deng, J., Ettema, S. L., & Murphy, B. (2020). Advanced pneumatic compression for treatment of lymphedema of the head and neck: A randomized wait-list controlled trial. *Supportive Care in Cancer*, 29(2), 795–803. <https://doi.org/10.1007/s00520-020-05540-8>
41. Samama, C. M., Afshari, A., Grønlykke, L., Madsen, M. H., Wiberg, S., & Romero, C. S. (2024). European guidelines on peri-operative venous thromboembolism prophylaxis: First update. *European Journal of Anaesthesiology*, 41(8), 561–569. <https://doi.org/10.1097/eja.0000000000002025>

42. Shires, C. B., Harris, P., & Dewan, K. (2022). Feasibility of machine-delivered sequential massage for the management of lymphedema in the head and neck cancer survivor. *Laryngoscope Investigative Otolaryngology*, 7(3), 774–778. <https://doi.org/10.1002/lio2.810>
43. Shishehbor, M. H., Powell, R. J., Montero-Baker, M. F., Dua, A., Martínez-Trabal, J. L., Bunte, M. C., Lee, A. C., Mugglin, A. S., Mills, J. L., Farber, A., & Clair, D. G. (2023). Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. *New England Journal of Medicine*, 388(13), 1171–1180. <https://doi.org/10.1056/nejmoa2212754>
44. Son, A., O'Donnell, T. F., Jr, Izhakoff, J., Gaebler, J. A., Niecko, T., & lafrati, M. A. (2019). Lymphedema-associated comorbidities and treatment gap. *Journal of vascular surgery. Venous and Lymphatic Disorders*, 7(5), 724–730. <https://doi.org/10.1016/j.jvsv.2019.02.015>
45. te Slaa, A., Dolmans, D. E., Ho, G. H., Mulder, P. G., van der Waal, J. C., de Groot, H. G., & van der Laan, L. (2011). Prospective randomized controlled trial to analyze the effects of intermittent pneumatic compression on edema following autologous femoropopliteal bypass surgery. *World Journal of Surgery*, 35(2), 446–454. <https://doi.org/10.1007/s00268-010-0858-9>
46. Won, Y. H., & Stubblefield, M. D. (2025b). Prevalence of function-limiting late effects in survivors of head and neck cancer. *PM&R*. <https://doi.org/10.1002/pmrj.13340>

Clinical Guideline Revision / History Information

Original Date: 7/31/2018

Reviewed/Revised: 7/23/2019, 7/21/2020, 08/04/2021, 12/01/2021, 07/26/2022, 07/19/2023, 07/29/2024, 11/1/2024, 02/01/2026